Enclomiphene: Preserving Fertility While on TRT

Last Updated: April 2024

Men with total testosterone below 300 ng/dL experience a 40% increased risk of all-cause mortality over an average follow-up of 10.8 years (Yeap et al., 2021, Clinical Endocrinology). Testosterone Replacement Therapy (TRT) effectively mitigates symptoms of hypogonadism, restoring vitality and metabolic health. However, a significant drawback of exogenous testosterone is its suppressive effect on the hypothalamic-pituitary-gonadal (HPG) axis, leading to impaired spermatogenesis and fertility. For men desiring to maintain fertility while on TRT, traditional co-therapy has often involved human chorionic gonadotropin (HCG). A newer, compelling alternative is enclomiphene citrate, an oral agent that offers distinct advantages for fertility preservation.

The Impact of TRT on Male Fertility

Exogenous testosterone, whether administered as testosterone cypionate or enanthate, directly signals the hypothalamus and pituitary gland to reduce the secretion of gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). This suppression is the core mechanism by which TRT improves testosterone levels but simultaneously impairs sperm production. LH is critical for stimulating Leydig cells in the testes to produce intratesticular testosterone (ITT), which is essential for spermatogenesis. FSH, on the other hand, directly supports Sertoli cells, which nurture developing sperm. When LH and FSH are suppressed, ITT plummets, and the environment for sperm maturation deteriorates, often leading to azoospermia (absence of sperm) or severe oligospermia (very low sperm count).

HCG Co-Therapy: The Traditional Approach

For decades, HCG has been the standard adjunctive therapy for fertility preservation during TRT. HCG is a glycoprotein hormone that mimics the action of LH. By binding to LH receptors on Leydig cells, HCG stimulates endogenous testosterone production within the testes, thereby maintaining ITT levels above the threshold required for robust spermatogenesis.

HCG Protocols and Considerations

Typical HCG dosages range from 500 to 1,000 IU administered subcutaneously, 2 to 3 times per week. This regimen aims to counteract the HPG axis suppression without significantly elevating systemic testosterone levels beyond the TRT dose. While effective, HCG co-therapy carries certain considerations:

• Administration: Requires frequent subcutaneous injections, adding to the patient’s injection burden.
• Cost: HCG can be expensive, and its availability has faced challenges in recent years.
• Estrogen Conversion: Increased Leydig cell activity from HCG can lead to elevated estradiol (E2) levels due to increased aromatization of testosterone. This may necessitate the co-administration of an aromatase inhibitor like anastrozole (e.g., 0.25-0.5 mg once or twice weekly) to keep E2 in the physiological range of 20-40 pg/mL (on TRT).
• Direct FSH Stimulation: HCG primarily acts as an LH mimetic. While maintaining ITT indirectly supports spermatogenesis, it does not directly stimulate FSH, which has its own role in Sertoli cell function.

Enclomiphene: A Modern Alternative for Fertility Preservation

Enclomiphene citrate is a selective estrogen receptor modulator (SERM) that has emerged as a promising alternative to HCG for maintaining fertility on TRT. Unlike HCG, enclomiphene works upstream, targeting the hypothalamus and pituitary to restore endogenous gonadotropin production.

Enclomiphene’s Mechanism of Action

Enclomiphene is the trans-isomer of clomiphene citrate. It acts as an estrogen receptor antagonist in the hypothalamus and pituitary gland. By blocking estrogen’s negative feedback at these sites, enclomiphene effectively “tricks” the HPG axis into believing estrogen levels are low. This disinhibition leads to an increased pulsatile release of GnRH from the hypothalamus, which, in turn, stimulates the pituitary to produce and secrete higher levels of both LH and FSH.

Increased LH directly stimulates Leydig cells to produce ITT, crucial for spermatogenesis. Simultaneously, increased FSH directly supports Sertoli cells, optimizing the testicular environment for sperm development. This direct, physiological stimulation of both LH and FSH sets enclomiphene apart from HCG, which primarily mimics LH.

“Enclomiphene citrate effectively stimulates endogenous gonadotropin release, thereby restoring normal serum testosterone concentrations while maintaining testicular function and fertility in men with secondary hypogonadism.” (Victor et al., 2017, Journal of Clinical Endocrinology & Metabolism)

Clinical Evidence for Enclomiphene

Several studies highlight enclomiphene’s efficacy in restoring and maintaining testicular function. For men with secondary hypogonadism, enclomiphene has been shown to increase total and free testosterone levels, often into the normal range, while also increasing LH and FSH. When used in conjunction with exogenous testosterone, it works to mitigate the suppressive effects of TRT on the HPG axis.

• In a multicenter, randomized, double-blind, placebo-controlled study, Victor et al. (2017) published in the Journal of Clinical Endocrinology & Metabolism demonstrated that enclomiphene citrate significantly increased total testosterone, LH, and FSH levels in men with secondary hypogonadism. This study underscored enclomiphene’s ability to restore hormonal balance by targeting the HPG axis.
• Ramasamy et al. (2014) in Fertility and Sterility explored oral enclomiphene citrate’s ability to stimulate gonadotropins and testosterone in men with secondary hypogonadism. Their findings indicated that enclomiphene successfully increased LH and FSH, leading to elevated endogenous testosterone production without the need for exogenous testosterone, thus preserving testicular volume and sperm production.

When integrated with TRT, enclomiphene can help maintain ITT and prevent testicular atrophy by keeping LH and FSH levels elevated, despite the systemic testosterone from injections. Typical dosages of enclomiphene for fertility preservation alongside TRT range from 12.5 mg daily to 25 mg daily, or 12.5 mg twice weekly.

Advantages of Enclomiphene Over HCG

• Oral Administration: Enclomiphene is an oral pill, eliminating the need for additional injections. This significantly improves patient convenience and adherence.
• Direct FSH Stimulation: Unlike HCG, which primarily mimics LH, enclomiphene stimulates both LH and FSH release from the pituitary. This comprehensive gonadotropin stimulation provides a more physiological approach to maintaining spermatogenesis.
• Potentially Lower E2 Fluctuations: By stimulating the body’s natural production, enclomiphene may lead to more controlled ITT and E2 levels compared to the surge often seen with HCG. While E2 still needs monitoring, the need for anastrozole might be less frequent or at lower doses.
• Cost-Effectiveness: In some regions, enclomiphene may offer a more cost-effective solution compared to long-term HCG use.

Enclomiphene vs. HCG: A Comparative Overview

Monitoring and Lab Work for Fertility Preservation

Regardless of the chosen co-therapy, comprehensive monitoring is paramount for men on TRT concerned about fertility.

Key Laboratory Parameters:

• Total Testosterone: Aim for 600–900 ng/dL mid-cycle